Extract of Indigofera spicata Exerts Antiproliferative Effects on Human Colorectal and Ovarian Carcinoma Cells
Authors:
- Galyna ShuvayevaGSGalyna Shuvayeva
- Mykola TupychakMTMykola Tupychak
- Olena VovkOVOlena Vovk
- Dmytro DemashDDDmytro Demash
- Svitlana ChernyshukSCSvitlana Chernyshuk
- Yaroslav BobakYBYaroslav Bobak
- Andriy ProkopivAPAndriy Prokopiv
- Nazariy PokhodyloNPNazariy Pokhodylo
- Leoni A. Kunz-SchughartLKLeoni A. Kunz-Schughart
- Mary T. FletcherMary T. Fletcher
- Oleh StasykOSOleh Stasyk
Open Access
Abstract
Metabolic anticancer therapy based on enzymatic arginine (Arg) deprivation (ADT) is currently being evaluated in clinical trials. The combination of ADT with low doses of the plant cytotoxic analogs of Arg, canavanine (Cav) or indospicine (Isp), have been proposed as being more efficient and selective against malignant cells. The leguminous plant Indigofera spicata contains one of the highest known amounts of Isp. Here we demonstrate for the first time that the Isp-containing ethanolic extract from I. spicata is growth-inhibiting and toxic for cultured human colorectal and ovarian carcinoma cells. The extract reduces the viability of colorectal carcinoma cells two-fold under Arg-deficient conditions and entirely abrogates their residual proliferative potential (growth recovery) after the treatment. Pre-exposure of the extract to recombinant human arginase I (rhARGI) as a therapeutic Arg-depleting agent did not impact the extract’s efficacy. Further development of Isp as a component of combinatorial anticancer metabolic targeting strategies is discussed.Keywords
Funding Information
- “Presidential Discretionary-Ukraine Support Grants” from Simons Foundation (SFI-PD-Ukraine-00014576, 0124U003831, 01DK24023, 0124U003964)
- National Research Foundation of Ukraine (NRFU) project N 2023.04/0048 (SFI-PD-Ukraine-00014576, 0124U003831, 01DK24023, 0124U003964)
- BMBF/BMFTR (SFI-PD-Ukraine-00014576, 0124U003831, 01DK24023, 0124U003964)
- MES of Ukraine (SFI-PD-Ukraine-00014576, 0124U003831, 01DK24023, 0124U003964)
This publication has 34 references indexed in Scilit:
- Metabolite fingerprinting of Urospatha sagittifolia (Araceae) tubers at different growth stages by multi-platform metabolomics and molecular networkingMicrochemical Journal, 2024
- Human arginase 1, a Jack of all trades?3 Biotech, 2022
- A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patientsInvestigational New Drugs, 2021
- Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancerCancer Medicine, 2021
- Amino acid metabolism as a therapeutic target in cancer: a reviewAmino Acids, 2021
- Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumorsInvestigational New Drugs, 2021
- A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinomaInvestigational New Drugs, 2021
- Indospicine combined with arginine deprivation triggers cancer cell death via caspase‐dependent apoptosisCell Biology International, 2020
- Arginine deprivation induces endoplasmic reticulum stress in human solid cancer cellsThe International Journal of Biochemistry & Cell Biology, 2016
- A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinomaInvestigational New Drugs, 2012